The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
The blood test screens individual blood donations for four common species of the parasite Babesia, which can cause anemia and other potentially fatal conditions.
The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.
While some large health systems have developed internal tools for lab test utilization, a number of outside vendors are rolling out solutions of their own.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
The company announced that it would begin offering seven proteomic tests at Colorado doctors' practices with up to four more to launch by the end of the year.
